Detalhe da pesquisa
1.
Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.
Diabetes Obes Metab
; 25(8): 2084-2095, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37013892
2.
Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M).
Diabetes Ther
; 13(5): 1053-1071, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35420397
3.
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin.
Diabetes Ther
; 13(7): 1299-1310, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35650350
4.
Development and First Use of the Patient's Qualitative Assessment of Treatment (PQAT) Questionnaire in Type 2 Diabetes Mellitus to Explore Individualised Benefit-Harm of Drugs Received During Clinical Studies.
Drug Saf
; 43(2): 119-134, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31679129
5.
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.
Curr Med Res Opin
; 36(4): 571-581, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31865758